Glycitein
Minor soy isoflavone (about 10% of total soy isoflavones) with oestrogenic activity. Less studied than genistein and daidzein but with similar pharmacological profile. Found primarily in soy germ fraction. Oestrogenic activity approximately 0.001% of oestradiol potency.
How it works (mechanism of action)
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
Oestrogenic activity — same precautions as other soy isoflavones. Hormone-sensitive conditions (ER+ breast cancer, endometrial cancer, uterine fibroids, endometriosis): AVOID. Thyroid function potential interference. Drug interactions: tamoxifen. Insufficient specific safety data.